奈达铂腹腔热灌注化疗治疗癌性腹腔积液的疗效观察及分析

李维; 王华庆; 赵阔; 钱正子; 周世勇; 张会来

doi:10.3969/j.issn.1000-8179.2012.22.013

奈达铂腹腔热灌注化疗治疗癌性腹腔积液的疗效观察及分析

Clinical Observation and Analysis of Nedaplatin Chemotherapy Using Intraperitoneal Hyperthermic Perfusion for Malignant Peritoneal Effusion

摘要

摘要:
目的研究抗肿瘤药物奈达铂腹腔热灌注治疗癌性腹腔积液的疗效和安全性。
方法自2012年2月至10月天津医科大学肿瘤医院综合内一科和淋巴肿瘤科共收治入组癌性腹腔积液患者35例，分为治疗组19例与对照组16例，治疗组患者用TRL型热化疗灌注机进行奈达铂腹腔热灌注化疗，对照组患者接受常规顺铂腹腔灌注化疗。每隔2天治疗一次，3次为1个疗程。分别在治疗前、治疗3次后及结束后4周进行实验室检查和临床观察，评价安全性和临床疗效。
结果腹腔热灌注化疗组完全缓解（CR）7例，部分缓解（PR）6例，平均缓解期2.9个月；常规腹腔灌注化疗组CR 3例，PR 2例，平均缓解期1.2个月，两组差异有统计学意义（P < 0.05）。在热灌注化疗组腹痛发生6例，常规灌注化疗组4例，两组差异无统计学意义（P>0.05）。
结论腹腔热灌注化疗可提高对癌性腹腔积液患者的疗效，毒副作用未增加。

Abstract:
Objective This work aims to observe the clinical effects of chemotherapy using intraperitoneal hyperthermic perfusion for malignant ascites.
Methods Thirty-five patients with malignant ascites were randomized into two groups, namely, the treatment group (Group A) and the control group (Group B). In Group A, 19 of the patients underwent an intraperitoneal hyperthermic perfusion and local thermotherapy. The other 16 patients in Group B received a conventional intraperitoneal perfusion.
Results Complete and partial remissions were achieved in 7 and 6 Group A patients, respectively, whereas in Group B, the numbers were 3 and 2, respectively. The effective rate was significantly higher in Group A compared with Group B (P < 0.05). In Group A, 4 of the patients suffered abdominal pains, whereas 6 suffered in Group B, the number was 6. No statistically significant differences were observed between the two groups (P>0.05).
Conclusion Nedaplatin chemotherapy using intraperitoneal hyperthermic perfusion can significantly improve the therapeutic effects of chemotherapy against malignant peritoneal effusion with very few side effects.

HTML全文

参考文献(14)

施引文献

资源附件(0)